HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study

Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational hepatology 2018-03, Vol.6 (1), p.25-34
Main Authors: Hu, Peng, Shang, Jia, Zhang, Wenhong, Gong, Guozhong, Li, Yongguo, Chen, Xinyue, Jiang, Jianning, Xie, Qing, Dou, Xiaoguang, Sun, Yongtao, Li, Yufang, Liu, Yingxia, Liu, Guozhen, Mao, Dewen, Chi, Xiaoling, Tang, Hong, Li, Xiaoou, Xie, Yao, Chen, Xiaoping, Jiang, Jiaji, Zhao, Ping, Hou, Jinlin, Gao, Zhiliang, Fan, Huimin, Ding, Jiguang, Zhang, Dazhi, Ren, Hong
Format: Article
Language:English
Subjects:
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous NA. Hepatitis B e antigen (HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA
ISSN:2225-0719
2310-8819
DOI:10.14218/JCTH.2017.00072